For research use only
| Cat No. | ABC-TC0504 |
| Product Type | Human Bone Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Bone |
| Product Code | KHOS312H |
KHOS-312H cell line provides a dependable osteosarcoma model for oncology research, cell signaling analysis, and anticancer drug development studies.
KHOS‑312H is a human osteosarcoma tumor cell line derived from bone tissue of a Caucasian female patient sampled at age 13. It is a virus-negative subclone derived from the KHOS/NP lineage and does not contain a rescuable Kirsten murine sarcoma virus genome. The cells exhibit adherent, fibroblast-like and epithelial-like morphology typical of osteosarcoma models, forming monolayers in vitro with an aneuploid karyotype consistent with transformed bone tumor cells. KHOS‑312H has been included in comparative osteosarcoma transcriptomic studies that profile gene and miRNA expression across multiple human osteosarcoma lines, indicating its relevance in molecular characterization of bone cancer. While the parental sarcoma lines are tumorigenic in animals, KHOS‑312H itself is reported to be non‑tumorigenic in immunosuppressed mice with colony growth in semisolid media, reflecting transformed but non‑metastatic behavior. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV‑1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | KHOS312H |
| Species | Human |
| Cat.No | ABC-TC0504 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Bone |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Bone Cancer Cell Lines |
KHOS‑312H is used as an in vitro human osteosarcoma model for studies of bone cancer biology, molecular signaling, and cell proliferation. It supports comparative analyses of gene and miRNA expression profiles across osteosarcoma models, investigation of drug response and phenotype modulation, and evaluation of anticancer therapeutic strategies in preclinical research.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
